KPIs & Operating Metrics(New)
Animal HealthAnimal Health Revenue AnnualBreakdown Of AssetsCardiovascularCardiovascular Revenue AnnualContractual ObligationsCost Of SalesDiabetesDisaggregated PharmaceuticalsDiversified BrandsEmployee StatisticsGross Margin (Quaterly) %Gross Profit (Quaterly)Hospital Acute CareImmunologyIncome Before Income TaxInventoriesNeuroscienceNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %OncologyOperating Expense SegregationOpex As A % Of Total Revenue %Profit By SegmentProfit By Segment AnnualProfit Margin By Segment %Profit Margin By Segment Annual %Property And Equipment SegregationProperty, Plant & Equipment By RegionRevenue By GeographyRevenue By Geography %Revenue By RegionRevenue By Region %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Revenue From Diabetes AnnualRevenue From Hospital Acute Care AnnualRevenue From Immunology AnnualRevenue From Neuroscience AnnualRevenue From Oncology AnnualRevenue From Vaccines AnnualVaccinesVirologyVirology Revenue AnnualWomen'S Health
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred Tax AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Assets (QoQ)Assets Growth (1y)Assets Growth (3y)Assets Growth (5y)Capital Expenditures (QoQ)Capital Expenditures Growth (1y)Capital Expenditures Growth (3y)Capital Expenditures Growth (5y)Cash & Equivalents (QoQ)Cash & Equivalents Growth (1y)Cash & Equivalents Growth (3y)Cash & Equivalents Growth (5y)Cash from Investing Activities (QoQ)Cash from Investing Activities Growth (1y)Cash from Investing Activities Growth (3y)Cash from Investing Activities Growth (5y)Cash from Operations (QoQ)Cash from Operations Growth (1y)Cash from Operations Growth (3y)Cash from Operations Growth (5y)Dividends Paid - Common (QoQ)Dividends Paid - Common Growth (1y)Dividends Paid - Common Growth (3y)Dividends Paid - Common Growth (5y)Dividends payables (QoQ)Dividends payables Growth (1y)Dividends payables Growth (3y)Dividends payables Growth (5y)EBIT (QoQ)EBIT Growth (1y)EBIT Growth (3y)EBIT Growth (5y)EBIT Margin (QoQ)EBIT Margin Growth (1y)EBIT Margin Growth (3y)EBIT Margin Growth (5y)EBITDA Margin (QoQ)EBITDA Margin Growth (1y)EBITDA Margin Growth (3y)EBITDA Margin Growth (5y)EBT (QoQ)EBT Growth (1y)EBT Growth (3y)EBT Growth (5y)EBT Margin (QoQ)EBT Margin Growth (1y)EBT Margin Growth (3y)EBT Margin Growth (5y)EPS (Basic) (QoQ)EPS (Basic) Growth (1y)EPS (Basic) Growth (3y)EPS (Basic) Growth (5y)EPS (Weighted Average and Diluted) (QoQ)EPS (Weighted Average and Diluted) Growth (1y)EPS (Weighted Average and Diluted) Growth (3y)EPS (Weighted Average and Diluted) Growth (5y)Enterprise Value (QoQ)Enterprise Value Growth (1y)Enterprise Value Growth (3y)Enterprise Value Growth (5y)FCF Margin (QoQ)FCF Margin Growth (1y)FCF Margin Growth (3y)FCF Margin Growth (5y)FCF Payout Ratio (QoQ)FCF Payout Ratio Growth (1y)FCF Payout Ratio Growth (3y)FCF Payout Ratio Growth (5y)Free Cash Flow (QoQ)Free Cash Flow Growth (1y)Free Cash Flow Growth (3y)Free Cash Flow Growth (5y)Gross Margin (QoQ)Gross Margin Growth (1y)Gross Margin Growth (3y)Gross Margin Growth (5y)Gross Profit (QoQ)Gross Profit Growth (1y)Gross Profit Growth (3y)Gross Profit Growth (5y)Interest Coverage Ratio (QoQ)Interest Coverage Ratio Growth (1y)Net Cash Flow (QoQ)Net Cash Flow Growth (1y)Net Cash Flow Growth (3y)Net Cash Flow Growth (5y)Net Income (QoQ)Net Income Growth (1y)Net Income Growth (3y)Net Income Growth (5y)Net Income towards Common Stockholders (QoQ)Net Income towards Common Stockholders Growth (1y)Net Income towards Common Stockholders Growth (3y)Net Income towards Common Stockholders Growth (5y)Net Margin (QoQ)Net Margin Growth (1y)Net Margin Growth (3y)Net Margin Growth (5y)Operating Income (QoQ)Operating Income Growth (1y)Operating Income Growth (3y)Operating Income Growth (5y)Operating Margin (QoQ)Operating Margin Growth (1y)Operating Margin Growth (3y)Operating Margin Growth (5y)Profit After Tax (QoQ)Profit After Tax Growth (1y)Profit After Tax Growth (3y)Profit After Tax Growth (5y)Property, Plant & Equipment (Net) (QoQ)Property, Plant & Equipment (Net) Growth (1y)Property, Plant & Equipment (Net) Growth (3y)Property, Plant & Equipment (Net) Growth (5y)Return on Assets (QoQ)Return on Assets Growth (1y)Return on Assets Growth (3y)Return on Assets Growth (5y)Return on Capital Employed (QoQ)Return on Capital Employed Growth (1y)Return on Capital Employed Growth (3y)Return on Capital Employed Growth (5y)Return on Equity (QoQ)Return on Equity Growth (1y)Return on Equity Growth (3y)Return on Equity Growth (5y)Return on Invested Capital (QoQ)Return on Invested Capital Growth (1y)Return on Invested Capital Growth (3y)Return on Invested Capital Growth (5y)Return on Sales (QoQ)Return on Sales Growth (1y)Return on Sales Growth (3y)Return on Sales Growth (5y)Revenue (QoQ)Revenue Growth (1y)Revenue Growth (3y)Revenue Growth (5y)Share-based Compensation (QoQ)Share-based Compensation Growth (1y)Share-based Compensation Growth (3y)Share-based Compensation Growth (5y)Shareholder's Equity (QoQ)Shareholder's Equity Growth (1y)Shareholder's Equity Growth (3y)Shareholder's Equity Growth (5y)Tax Rate (QoQ)Tax Rate Growth (1y)Tax Rate Growth (3y)Tax Rate Growth (5y)Total Debt (QoQ)Total Debt Growth (1y)Total Debt Growth (3y)Total Debt Growth (5y)
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned
Merck (MRK) Divestments (2020 - 2021)
Generated on {Timestamp}
© BusinessQuant.com
Generated on {Timestamp}
Powered by 
Merck (MRK) has disclosed Divestments for 6 consecutive years, with -$82.0 million as the latest value for Q2 2021.
- On a quarterly basis, Divestments changed N/A to -$82.0 million in Q2 2021 year-over-year; TTM through Mar 2022 was -$82.0 million, a 59.41% increase, with the full-year FY2021 number at -$134.0 million, up 46.4% from a year prior.
- Divestments was -$82.0 million for Q2 2021 at Merck, down from -$52.0 million in the prior quarter.
- In the past five years, Divestments ranged from a high of -$52.0 million in Q1 2021 to a low of -$82.0 million in Q2 2021.
Peer Comparison
Historic Data
Download Data 🔒| Date | Value |
|---|---|